Pith. sign in

REVIEW 3 major objections 5 minor 27 references

PRECEDE revises a parent drug to reduce a named side effect by transferring strategies from historical safety-driven redesigns, checking mechanism before any edit.

Reviewed by Pith at T0; open to challenge. T0 means a machine referee read the full paper against a public rubric. the ladder, T0–T4 →

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗

PRECEDE redesigns parent drugs to mitigate a specified side effect by classifying liability mechanism, transferring strategies from historical precedents, and ranking candidates with in silico proxies under human checkpoints.

T0 review reviewed 2026-07-12 challenge →

load-bearing objection Clear task framing and control-flow design for safety-driven redesign; the transfer claim is still an untested architectural hypothesis, not a result. the 3 major comments →

arxiv 2607.02944 v1 pith:JNPQDNFE submitted 2026-07-03 cs.LG cs.AI

A Precedent-Guided Co-Scientist for Side-Effect-Aware Drug Redesign

Yujin Kim , Charmgil Hong This is my paper
classification cs.LG cs.AI
keywords side-effect-aware drug redesignprecedent memoryLLM orchestratorattribution-aware routinghistorical replayhuman-supervised AIdrug safety optimizationevidence grounding
verification ladder T0 review T1 audit T2 compute T3 formal T4 reserved

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

PRECEDE treats side-effect-aware drug redesign as evidence-grounded, precedent-guided reasoning rather than free molecular generation. Given an approved parent drug and a documented side effect, it first corroborates the association, classifies the liability by mechanism, and only then admits redesignable cases to strategy transfer and constrained editing. Strategies are abstracted from structured historical redesign records and used to propose candidates that are scored for toxicity reduction while preserving therapeutic proxies, with every evidence item and decision logged. Human review gates non-redesignable cases, conflicts, and final triage. A sympathetic reader cares because many useful drugs are limited by known safety liabilities, and the workflow aims to keep redesign hypotheses auditable, falsifiable against past medicinal-chemistry decisions, and bounded by prior pharmacology.

Core claim

The paper claims that side-effect-aware redesign of an existing drug can be performed as a precedent-guided agentic workflow: classify the side effect by mechanism before any structural edit, transfer an abstracted strategy from structured historical redesign records, and return ranked candidates with evidence trails and in silico efficacy–safety profiles under explicit policies and human checkpoints.

What carries the argument

Attribution-aware routing plus precedent memory: the side effect is placed in one of five mechanism categories; only redesignable liabilities proceed, and transferable strategies (such as exposure modulation or liability-group replacement) are abstracted from structured parent–issue–modification–successor records to guide constrained candidate generation.

Load-bearing premise

The load-bearing premise is that strategies taken from a modest set of past redesigns, scored with docking and toxicity predictors, transfer well enough to new parent compounds that the ranked candidates are scientifically meaningful.

What would settle it

On held-out historical parent–successor trajectories, check whether PRECEDE recovers the documented optimization strategy (or an equivalent redesign) from the parent and side effect alone, without the successor stored in memory, and whether multi-rater expert review finds the rationales plausible.

Watch this falsifier. Get emailed when new claim-graph text bears on it.

If this is right

  • Redesign hypotheses can be ranked and audited against drug–side-effect databases and knowledge graphs before any synthesis is considered.
  • Historical replay on held-out parent–successor pairs can test whether the reasoning recovers documented safety-driven optimizations.
  • Target-mediated or insufficient-evidence cases are halted for human review rather than force-edited.
  • Every evidence item, precedent, edit, score, and human intervention is logged into an auditable redesign report.
  • The same precedent-guided pattern is positioned as extensible to other constrained design tasks beyond side-effect mitigation.

Where Pith is reading between the lines

These are editorial extensions of the paper, not claims the author makes directly.

  • If strategy transfer holds up, medicinal chemists could use the system as a rapid first-pass filter for known liability classes instead of restarting each redesign from scratch.
  • Public side-effect databases that under-report rare effects, and proxies that only loosely match the true liability (for example hepatic clearance for renal exposure), would systematically limit when the ranked candidates are trustworthy.
  • Growing the precedent memory beyond the seed cases will require reliable mining of medicinal-chemistry literature with strategy labels, which the paper flags as future work.
  • An attribution-before-generation gate could transfer to other constrained redesign problems, such as removing metabolic soft spots while keeping the pharmacophore.
Share X Bluesky LinkedIn Reddit HN

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, simulated authors' rebuttal, and a circularity audit.

Referee Report

3 major / 5 minor

Summary. The manuscript proposes PRECEDE, an LLM-orchestrated, human-supervised workflow for side-effect-aware drug redesign: given a parent drug, a documented side effect, and optional therapeutic context, the system corroborates the association (SIDER/OnSIDES/PrimeKG), classifies the liability into one of five mechanism categories before any edit, retrieves and abstracts strategies from a structured precedent memory, generates constrained candidates (MMP, bioisosteres, REINVENT Mol2Mol), and ranks them with docking, ADMET proxies, parent similarity, and synthetic accessibility under explicit decision policies and provenance logging. Only redesignable categories proceed; target-mediated and insufficient-evidence cases halt at human review. The main proposed evaluation is historical replay on 30–50 held-out safety-driven redesign trajectories; a proof-of-concept implementation is illustrated with a cidofovir control-flow walkthrough and two exception cases (warfarin, terfenadine).

Significance. If the architecture and transfer assumptions hold under the planned historical-replay pilot, PRECEDE would offer a useful framing for safety-driven redesign that is distinct from de novo property-score optimization: mechanism attribution before generation, strategy transfer from structured precedents, and auditable hypotheses bounded by human checkpoints. Strengths already present in the manuscript include a clear task definition, an attribution-aware redesignability gate with demonstrated reject branches (Appendix A.5), a falsifiable replay protocol that holds out successors, transparent composite scoring, and explicit governance/dual-use limitations. These design choices are valuable even as an architectural contribution for the AI-for-science community; the operational claim that ranked candidates are scientifically meaningful redesigns, however, remains contingent on the pilot results that the paper itself marks as necessary.

major comments (3)
  1. §3 and Appendix A.3 define historical replay on 30–50 held-out parent→successor trajectories as the main falsifiable test of whether PRECEDE recovers documented optimization logic. No replay results, baselines, or even a completed pilot subset are reported—only a protocol and targets (Table 1). The central operational claim that the system produces useful, efficacy-preserving, side-effect-mitigating redesign hypotheses therefore remains an architectural hypothesis. For the claim to be load-bearing rather than aspirational, the pilot (or a reduced but fully reported subset with strategy-level F1, success-criterion rates, and disagreement analysis) needs to be executed and discussed.
  2. Table 2 lists only four seed precedents; Appendix A.5’s cidofovir walkthrough transfers “exposure modulation” from TDF→TAF and ranks candidates using Clearance Microsome AZ as a primary safety endpoint for a renal-toxicity query. The manuscript correctly notes that hepatic microsomal clearance is an indirect proxy for renal exposure, yet accept/rank decisions and the composite score (weights 0.45/0.30/0.15/0.10; efficacy margin 2.0 kcal/mol) rest on these choices. Without evidence that abstracted strategies from a small hand-curated memory transfer reliably—and that the chosen proxies correlate with the targeted liability—the ranking and “efficacy preserved / toxicity improved” conclusions are self-consistent with the tool stack rather than scientifically validated. Either expand and ablate the precedent memory and proxy panel, or substantially narrow claims to control-flow and auditabil
  3. §2 and Appendix A.4 leave free parameters (evidence confidence threshold, composite ranking weights, parent-relative docking margin, reflection-loop bounds) fixed without sensitivity analysis or justification against alternatives. Because these parameters gate stage transitions and final ranking, the evaluation roadmap should include at least a minimal sensitivity or ablation study once replay data exist; otherwise reported success rates will be hard to interpret.
minor comments (5)
  1. Figure 1 is readable but the feedback/iteration and human-oversight paths could be labeled more explicitly to match the three checkpoints in §4 and A.6.
  2. Table 4 reports a docking delta of −0.30 kcal/mol as improvement; briefly state the sign convention (more negative = better) in the table caption for non-docking readers.
  3. A.1’s comparison to DrugAgent and LIDDIA is clear; a short sentence on how PRECEDE differs from property-conditioned generative optimizers (e.g., REINVENT alone, JT-VAE-style objectives) would further situate the contribution for the ML audience.
  4. Typos/formatting: “We defineside-effect-aware” (§1); occasional missing spaces after periods in the arXiv text; ensure consistent notation for parent x / candidates x′_i.
  5. Appendix A.2 mentions Cohen’s κ for expert review; specify the planned number of raters and blinding procedure more tightly if the pilot is run.

Circularity Check

0 steps flagged

No circular derivation: PRECEDE is an architectural proposal with held-out historical replay, not a prediction forced by its own inputs.

full rationale

This manuscript proposes an LLM-orchestrated workflow (attribution routing, precedent memory, constrained redesign, in silico evaluation) and a pilot evaluation protocol. It does not claim a first-principles derivation or a fitted law that is then re-presented as prediction. The main falsification design—historical replay on 30–50 trajectories with successors held out—is explicitly non-circular by construction: the system must recover documented optimizations from parent drug and side effect alone. The cidofovir walkthrough is labeled as a control-flow demonstration, not biological validation, and the authors note that microsomal clearance is only an indirect proxy. Seed precedents (Table 2) and hand-chosen composite-score weights are ordinary systems-design choices; they are not redefined as external predictions. Citations for mechanism taxonomies, tools, and case studies are external (Edwards & Aronson, SIDER, PrimeKG, Rautio et al., etc.); there is no load-bearing self-citation uniqueness theorem or ansatz smuggled from the same authors. No equation or claim reduces a reported result to its own fitted target. Correctness risk (whether four seed strategies plus docking/ADMET proxies transfer scientifically) is real but is an evidence gap, not circularity.

Axiom & Free-Parameter Ledger

4 free parameters · 4 axioms · 3 invented entities

As a systems proposal, the load-bearing content is not a fitted physical law but a stack of domain assumptions (side-effect taxonomies, database reliability, strategy transfer, proxy adequacy) plus hand-set policy thresholds and score weights that gate redesign and ranking. Invented entities are organizational (orchestrator, precedent records, routing categories), not new physical objects; independent evidence for their utility awaits the unfinished pilot.

free parameters (4)
  • evidence confidence threshold = e.g. SIDER support or fewer than two citations triggers expansion/halt
    Stage transitions require SIDER-confirmed association or ≥2 citations (and similar confidence rules); exact cutoffs are policy choices that decide whether redesign proceeds.
  • composite ranking weights = 0.45 / 0.30 / 0.15 / 0.10
    Walkthrough ranks with fixed weights: safety endpoint delta 0.45, docking 0.30, parent Tanimoto 0.15, SA 0.10; these determine which candidate is rank-1.
  • parent-relative efficacy margin = 2.0 kcal/mol
    Docking degradation beyond a parent-relative margin (stated 2.0 kcal/mol in walkthrough) fails evaluation and returns to redesign.
  • seed precedent memory size and contents = 4 seed cases (Table 2)
    Proof-of-concept uses four hand-curated parent→successor records that drive strategy abstraction for the walkthrough.
axioms (4)
  • domain assumption Adverse drug reactions can be operationally partitioned into five mechanism categories that determine whether structural redesign is scientifically defensible.
    §2 attribution-aware routing cites Edwards & Aronson / Aronson & Ferner / Park et al. taxonomies and routes only categories (ii)–(iv) to redesign.
  • domain assumption Strategies abstracted from historical safety-driven redesigns transfer to new parents that share attribution category and therapeutic context.
    Core of §2 precedent memory and the cidofovir walkthrough transferring TDF→TAF exposure modulation without a stored cidofovir successor.
  • domain assumption Public resources (SIDER, OnSIDES, PrimeKG) and in silico proxies (docking, ADMET-AI, SA, Tanimoto) are adequate to ground associations and rank redesign hypotheses for pilot evaluation.
    Evidence grounding and redesign quality axes in §3 and A.2; limitations section notes under-reporting and domain shift.
  • ad hoc to paper Historical replay agreement with documented successors is a necessary (though not sufficient) test of medicinal-chemistry reasoning.
    §3 evaluation roadmap treats held-out parent→successor trajectories as the main falsifiable benchmark.
invented entities (3)
  • PRECEDE LLM orchestrator with explicit policies and human-review checkpoints no independent evidence
    purpose: Coordinate evidence grounding, attribution, precedent retrieval, constrained redesign, evaluation, and provenance logging as a co-scientist workflow.
    The system is the paper’s primary contribution; independent utility is not yet shown beyond a single walkthrough and seed memory.
  • Structured precedent memory (parent, safety issue, modification, successor, outcome → transferable strategy) no independent evidence
    purpose: Encode redesign cases as strategy-bearing records rather than isolated molecules for analogy-based transfer.
    Table 2 seed memory and §2 strategy abstraction; no large validated corpus yet.
  • Attribution-aware redesignability gate (five-way classification before any structural edit) no independent evidence
    purpose: Block target-mediated and insufficient-evidence cases from automatic editing and force human review.
    §2 routing policy; exception cases in A.5 demonstrate branching but not external validation of classification accuracy.

reviewed 2026-07-12 · how reviews work

0 comments
Cite this review

Pith. "Pith review of A Precedent-Guided Co-Scientist for Side-Effect-Aware Drug Redesign." pith.science (2026). https://pith.science/paper/JNPQDNFE

@misc{pith2026260702944,
  author       = {Pith},
  title        = {Pith review of: A Precedent-Guided Co-Scientist for Side-Effect-Aware Drug Redesign},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/JNPQDNFE}},
  note         = {Machine review of arXiv:2607.02944}
}
Share X Bluesky LinkedIn Reddit HN
read the original abstract

We propose PRECEDE, a precedent-guided co-scientist for side-effect-aware drug redesign that revises a parent compound to mitigate a specified side effect while preserving therapeutic function. Rather than isolated molecular generation, PRECEDE frames redesign as evidence-grounded reasoning over drug--side-effect associations, biomedical knowledge graphs, and precedents of safety-driven optimization, coordinated by an LLM orchestrator with explicit policies and human-review checkpoints. We position PRECEDE as a human-supervised AI-for-science workflow in which hypotheses remain auditable, falsifiable, and bounded by prior pharmacology.

Figures

Figures reproduced from arXiv: 2607.02944 by Charmgil Hong, Yujin Kim.

Figure 1
Figure 1. Figure 1: Overview of PRECEDE, an LLM-orchestrated workflow for evidence-grounded, precedent-guided drug redesign. (i) target-mediated, (ii) off-target structural liability, (iii) metabolism or reactive intermediate, (iv) exposure or phar￾macokinetic, and (v) insufficient evidence. Only categories (ii)–(iv) proceed to redesign; categories (i) and (v) are routed to human review. This routing keeps structural editing … view at source ↗
Figure 2
Figure 2. Figure 2: Docked poses on viral DNA polymerase (PDB 9JA3). Green: cidofovir (parent); cyan: generated analog [PITH_FULL_IMAGE:figures/full_fig_p006_2.png] view at source ↗

discussion (0)

Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.

Reference graph

Works this paper leans on

27 extracted references · 2 linked inside Pith

  1. [1]

    Nucleic acids research , volume=

    The SIDER database of drugs and side effects , author=. Nucleic acids research , volume=. 2016 , publisher=

    2016

  2. [2]

    International conference on machine learning , pages=

    Junction tree variational autoencoder for molecular graph generation , author=. International conference on machine learning , pages=. 2018 , organization=

    2018

  3. [3]

    Med , volume=

    OnSIDES database: Extracting adverse drug events from drug labels using natural language processing models , author=. Med , volume=. 2025 , publisher=

    2025

  4. [5]

    arXiv preprint arXiv:2505.09388 , year=

    Qwen3 technical report , author=. arXiv preprint arXiv:2505.09388 , year=

    Pith/arXiv arXiv

  5. [6]

    Journal of chemical information and modeling , volume=

    Computationally efficient algorithm to identify matched molecular pairs (MMPs) in large data sets , author=. Journal of chemical information and modeling , volume=. 2010 , publisher=

    2010

  6. [7]

    Bioinformatics , volume=

    ADMET-AI: a machine learning ADMET platform for evaluation of large-scale chemical libraries , author=. Bioinformatics , volume=. 2024 , publisher=

    2024

  7. [8]

    Nucleic acids research , volume=

    UniProt: the universal protein knowledgebase , author=. Nucleic acids research , volume=. 2018 , publisher=

    2018

  8. [9]

    Nucleic acids research , volume=

    RCSB Protein Data Bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences , author=. Nucleic acids research , volume=. 2021 , publisher=

    2021

  9. [10]

    Nucleic acids research , volume=

    ChEMBL: a large-scale bioactivity database for drug discovery , author=. Nucleic acids research , volume=. 2012 , publisher=

    2012

  10. [11]

    Journal of computational chemistry , volume=

    AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , author=. Journal of computational chemistry , volume=. 2010 , publisher=

    2010

  11. [12]

    Journal of Cheminformatics , volume=

    Reinvent 4: Modern AI--driven generative molecule design , author=. Journal of Cheminformatics , volume=. 2024 , publisher=

    2024

  12. [13]

    Chase, Harrison , month = oct, title =

  13. [14]

    Advances in neural information processing systems , volume=

    Graph convolutional policy network for goal-directed molecular graph generation , author=. Advances in neural information processing systems , volume=

  14. [15]

    Scientific reports , volume=

    Optimization of molecules via deep reinforcement learning , author=. Scientific reports , volume=. 2019 , publisher=

    2019

  15. [16]

    arXiv 2025 , author=

    DrugAgent: Automating AI-Aided Drug Discovery Programming through LLM Multi-Agent Collaboration. arXiv 2025 , author=. arXiv preprint arXiv.2411.15692 , year=

    Pith/arXiv arXiv 2025

  16. [17]

    Proceedings of the 2025 Conference on Empirical Methods in Natural Language Processing , pages=

    Liddia: Language-based intelligent drug discovery agent , author=. Proceedings of the 2025 Conference on Empirical Methods in Natural Language Processing , pages=

    2025

  17. [18]

    Scientific Data , volume=

    Building a knowledge graph to enable precision medicine , author=. Scientific Data , volume=. 2023 , publisher=

    2023

  18. [19]

    AgentDrug: Utilizing Large Language Models in An Agentic Workflow for Zero-Shot Molecular Editing , author=

  19. [20]

    Nature reviews drug discovery , volume=

    The expanding role of prodrugs in contemporary drug design and development , author=. Nature reviews drug discovery , volume=. 2018 , publisher=

    2018

  20. [21]

    arXiv preprint arXiv:2403.02706 , year=

    Deepbioisostere: Discovering bioisosteres with deep learning for a fine control of multiple molecular properties , author=. arXiv preprint arXiv:2403.02706 , year=

    arXiv

  21. [22]

    The twelfth international conference on learning representations , year=

    Conversational drug editing using retrieval and domain feedback , author=. The twelfth international conference on learning representations , year=

  22. [23]

    arXiv preprint arXiv:2410.13147 , year=

    AgentDrug: Utilizing Large Language Models in An Agentic Workflow for Zero-Shot Molecular Optimization , author=. arXiv preprint arXiv:2410.13147 , year=

    arXiv

  23. [24]

    Antiviral research , volume=

    Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus , author=. Antiviral research , volume=. 2016 , publisher=

    2016

  24. [25]

    The Lancet , volume=

    Adverse drug reactions: definitions, diagnosis, and management , author=. The Lancet , volume=. 2000 , publisher=

    2000

  25. [26]

    Joining the

    Aronson, Jeffrey K and Ferner, Robin E , journal=. Joining the

  26. [27]

    Nature Reviews Drug Discovery , volume=

    Managing the challenge of chemically reactive metabolites in drug development , author=. Nature Reviews Drug Discovery , volume=. 2011 , publisher=

    2011

  27. [28]

    Journal of Medicinal Chemistry , volume=

    Matched molecular pair analysis: significance and the impact of experimental uncertainty , author=. Journal of Medicinal Chemistry , volume=

This paper was first reviewed by grok-4.5 on July 12, 2026.